SCHEMBL7307461

SCHEMBL7307461

CCOC(C)N1CCNCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.37
SLC6A2 P23975 11/20 0.36
SLC6A4 P31645 11/20 0.36
KCNH2 Q12809 5/20 0.35
CYP2D6 P10635 4/20 0.35
CYP3A4 P08684 3/20 0.35
SLC6A3 Q01959 3/20 0.35
CACNA1F O60840 2/20 0.35
CACNA1D Q01668 2/20 0.35
CACNA1S Q13698 2/20 0.35
CACNA1C Q13936 2/20 0.35
LMNA P02545 1/20 0.35
CHRM5 P08912 1/20 0.32
CHRM3 P20309 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
THRB P10828 1/20 0.31
SIGMAR1 Q99720 1/20 0.30
OPRD1 P41143 1/20 0.30
HTR7 P34969 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8039857 1.00 SMN1; SMN2 (0.37) SMN1; SMN2SLC6A2SLC6A4KCNH2CYP2D6
SCHEMBL14141933 0.84 LMNA (0.39) SMN1; SMN2SLC6A2SLC6A4KCNH2CYP2D6
SCHEMBL11818265 0.83 SLC6A2 (0.38) SMN1; SMN2SLC6A2SLC6A4KCNH2CYP2D6
SCHEMBL16266998 0.80 SLC6A2 (0.36) SMN1; SMN2SLC6A2SLC6A4KCNH2CYP2D6
SCHEMBL3309160 0.79 LMNA (0.39) LMNATHRB
SCHEMBL14142190 0.79 SMN1; SMN2 (0.35) SMN1; SMN2SLC6A2SLC6A4KCNH2CYP2D6
SCHEMBL10928292 0.78 SLC6A2 (0.35) SMN1; SMN2SLC6A2SLC6A4KCNH2CYP2D6
SCHEMBL13263 0.78 SMN1; SMN2 (0.38) SMN1; SMN2SLC6A2SLC6A4KCNH2CHRM5
SCHEMBL14142349 0.78 SMN1; SMN2 (0.34) SMN1; SMN2SLC6A2SLC6A4KCNH2
Bromide SCHEMBL2354969 0.77 LMNA (0.38) LMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3851531-A1 ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN Sarepta Therapeutics, Inc. (US) 2021-07-21 EP disclosed
CN-101812060-B Simple novel method for preparing high-purity Sprycel, and intermediate compound NANJING CAVENDISH BIOENGINEERING TECHNOLOGY CO LTD 2011-08-17 CN disclosed
CN-101845045-A Novel method for synthesizing dasatinib NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD 2010-09-29 CN disclosed
CN-101812060-A Simple novel method for preparing high-purity Sprycel, and intermediate compound NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD 2010-08-25 CN disclosed
EP-0839805-B1 Pyrrolidinone derivatives and their use as antipsychotic medicaments SCHERING AG (DE) 2001-10-04 EP disclosed
US-5969138-A ANTIPSYCHOTIC AGENTS MITSUI CHEMICALS, INC. (JP) 1999-10-19 US disclosed
EP-0839805-A1 Pyrrolidinone derivatives and their use as antipsychotic medicaments MITSUI TOATSU CHEMICALS, INC. (JP) 1998-05-06 EP disclosed